PDS Biotechnology Corporation
PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developingā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.69
Price-1.85%
-$0.01
1Y
Price
Market Cap
$38.368m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$33.356m
+7.2%
1y CAGR+4.9%
3y CAGR-31.7%
5y CAGREPS
-$0.67
+19.4%
1y CAGR+16.0%
3y CAGR-17.1%
5y CAGRBook Value
$3.893m
$24.663m
Assets$20.770m
Liabilities$15.861m
DebtDebt to Assets
64.3%
-0.6x
Debt to EBITDAFree Cash Flow
-$4.390b
+7.9%
1y CAGR-9.0%
3y CAGR-33.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company